ATE187721T1 - (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen - Google Patents

(3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE187721T1
ATE187721T1 AT92920778T AT92920778T ATE187721T1 AT E187721 T1 ATE187721 T1 AT E187721T1 AT 92920778 T AT92920778 T AT 92920778T AT 92920778 T AT92920778 T AT 92920778T AT E187721 T1 ATE187721 T1 AT E187721T1
Authority
AT
Austria
Prior art keywords
group
pharmaceutical compositions
formula
alkyl
tetrahydrocannabinol
Prior art date
Application number
AT92920778T
Other languages
English (en)
Inventor
Raphael Mechoulam
Aviva Breuer
William Devane
Summer H Burstein
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE187721T1 publication Critical patent/ATE187721T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT92920778T 1991-09-12 1992-09-11 (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen ATE187721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL99468A IL99468A (en) 1991-09-12 1991-09-12 (3s, 4s)-delta- 6-tetrahydrocannabinol- 7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
PCT/US1992/007718 WO1993005031A1 (en) 1991-09-12 1992-09-11 (3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE187721T1 true ATE187721T1 (de) 2000-01-15

Family

ID=11062883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92920778T ATE187721T1 (de) 1991-09-12 1992-09-11 (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen

Country Status (8)

Country Link
EP (1) EP0642504B1 (de)
JP (1) JP3298881B2 (de)
AT (1) ATE187721T1 (de)
AU (1) AU664204B2 (de)
CA (1) CA2118929C (de)
DE (1) DE69230446T2 (de)
IL (1) IL99468A (de)
WO (1) WO1993005031A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
EP1071419B1 (de) 1998-04-21 2007-07-25 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cannabinoiden als antioxidantien und neuroschützende mittel
AU2002319422C1 (en) * 2001-07-10 2008-05-01 Norton Healthcare Limited Aerosol formulations of delta8 tetrahydrocannabinol
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (de) * 2002-02-01 2019-05-08 GW Pharma Limited Zusammensetzungen mit cannabidiolsäure zur behandlung von übelkeit, erbrechen, emesis, reisekrankheit oder ähnlichen zuständen
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833073A (en) * 1987-01-27 1989-05-23 Hoffmann-La Roche Inc. Immunoassay for tetrahydrocannabinol metabolites
US5144030A (en) * 1987-02-17 1992-09-01 Abbott Laboratories Fluorescene polarization immunoassay for tetrahydrocannabinoids
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5036014A (en) * 1989-01-31 1991-07-30 Elsohly Mahmoud A Deuterated cannabinoids as standards for the analysis of tetrahydrocannabinol and its metabolites in biological fluids

Also Published As

Publication number Publication date
IL99468A (en) 1997-09-30
EP0642504B1 (de) 1999-12-15
CA2118929A1 (en) 1993-03-18
AU2678792A (en) 1993-04-05
EP0642504A4 (de) 1994-08-22
JP3298881B2 (ja) 2002-07-08
IL99468A0 (en) 1992-08-18
EP0642504A1 (de) 1995-03-15
DE69230446D1 (de) 2000-01-20
JPH07505119A (ja) 1995-06-08
CA2118929C (en) 2004-04-27
WO1993005031A1 (en) 1993-03-18
DE69230446T2 (de) 2000-04-13
AU664204B2 (en) 1995-11-09

Similar Documents

Publication Publication Date Title
AU1463195A (en) Substituted aromatic compounds as c.amp phosphodiesterase- and tnf-inhibitors
EP0389282A3 (de) Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
ATE79376T1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69230446D1 (de) (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE3850603D1 (de) Arylaralkylether, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung.
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
EP0605474A4 (de)
KR860008973A (ko) 2-피롤리돈 유도체
ES2071786T3 (es) Compuestos bloqueadores de nmda, composiciones farmaceuticas, su preparacion y su uso.
ATE13882T1 (de) 1-((substituierte-naphthyl)aethyl)imidazolderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
PT96003A (pt) Processo para a preparacao de composicoes farmaceuticas, contendo um derivado triazol
ATE23150T1 (de) Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE36154T1 (de) 4-phenylaminopyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE3063105D1 (en) Clavulanic acid derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties